This in-vitro resistance to fludarabine therapy is supported by in-vivo data showing that patients whose CLL cells expressed low levels of Lck were less likely to achieve a partial or complete response when being treated with this drug (Table 1). Here, LCK is linked to B-cell chronic lymphocytic leukemia.